|
Nephrectomy after response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A surgical challenge allowing favorable oncological outcomes. |
|
|
Honoraria - Astellas Pharma; Ipsen; Janssen-Cilag; Roche |
Consulting or Advisory Role - Janssen-Cilag; MSD Oncology (Inst); Novartis (Inst); Roche |
Travel, Accommodations, Expenses - Ferring; Intuitive Surgical; Ipsen; Janssen-Cilag; Pfizer; Roche |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Ipsen; Takeda |
Travel, Accommodations, Expenses - Astellas Pharma; Intuitive Surgical; Janssen; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen |
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Merck KGaA; MSD Oncology |
|
|
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Consulting or Advisory Role - Ipsen; MSD |
|
|
Consulting or Advisory Role - Astellas Pharma; Ipsen |
|
|
Research Funding - Novartis (Inst) |
Expert Testimony - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Novartis; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); MSD (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); IPSEN (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
Speakers' Bureau - Amgen (Inst); Astellas Pharma (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Sanofi/Aventis (Inst) |
Research Funding - BMS (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi |
|
|
Honoraria - Astellas Pharma; EUSA Pharma |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Roche |